Fundacion Para La Investigacion Medica Aplicada

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Other

Modernatx, Inc.

Research Center Borstel

Proyecto De Biomedicina Cima, S.l.

Pedro Berraondo Lopez

Claude Leclerc

Antonio Fontanellas Roma

Kerry Benenato

Stephen G Hoge

Vladimir Presnyak

Ellalahewage Sathyajith Kumarasinghe

Iain McFadyen

Paolo Martini

Staci Sabnis

Lin Tung Guey

Maria Del Carmen Ochoa Nieto

Ignacio Javier Melero Bermejo

Francisco De Asis Palazon Garcia

Silvia Bulfone-Paus

Lei Jiang

Irantzu Serrano Mendioroz

Matias Antonio Avila Zaragoza

Erwin Hans Duitmann

Oscar Alvarez Guerras

Borja Barrachina Larraza

Jessica Fioravanti

Jose Medina Echeverz

Francisco De Palazon Garcia

Erwin Duitman

Maria Del Ochoa Nieto

The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).

Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria

The present disclosure relates to human porphobilinogen deaminase derived proteins and polynucleotides and methods of using these proteins and polynucleotides.

Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof

The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises:

Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response

Systems and methods for estimating hemodynamic parameters from physiological curve images. A mobile device captures pictures of a physiological monitor display, which are used to extract the relevant physiological curve and upload it to an analysis server for processing and estimation of hemodynamic parameters. In some examples, the mobile device runs a dedicated application and is Internet-connected, which in turn connects to an Internet-connected analysis server. In some further examples, the system can be implemented using any computer that is capable of taking an image, extracting a physiological curve, and uploading it to a network service for analysis. In still further examples, analysis can be performed by the mobile device instead of via a remote server.

Systems and methods for estimating hemodynamic parameters from a physiological curve image

The invention relates to a kit of parts, suitable for use in a therapy of cancer, wherein said kit comprises: (i) a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several tumor-associated antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells or a mixture of such recombinant proteins wherein at least one of said epitopes, or tumor associated antigens, or insertion sites of CyaA protein, or fragment of said CyaA protein is different between the various recombinant proteins in the mixture; and said kit of parts further comprises at least one of the following compounds;(ii) an agent, suitable for modulating a regulatory immune response in a patient ad optionally;(iii) an adjuvant component suitable for activating the innate immune response in a patient.

The present invention relates to compositions capable of promoting both the innate immune response as well as the adaptive immune response in a subject based on the jointly use of ApoA, interleukin 15 and the Sushi domain of the IL15 receptor alpha chain, as well as to the use of these compositions for the stimulation of the immune response in a patient and to therapeutic methods for the treatment of infectious and neoplastic diseases.

Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same

Growing community of inventors

Pamplona, Spain

Pedro Berraondo Lopez